Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...
Amgen’s proposed acquisition of Horizon Therapeutics for $28.7 billion, including debt, would be the largest healthcare deal since AstraZeneca’s $39 billion purchase of...
From next year, GSK’s top management will be led by a double female team, a pioneering move for the global pharmaceutical industry. The UK drugs giant this week announced...
EU competition authorities have approved AstraZeneca’s $39 billion takeover of US biopharma Alexion. Europe’s green light for the deal sealed in December 2020 follows the...
AstraZeneca’s agreement to acquire Alexion Pharma for $39 billion, sealed in December 2020 and approved by the US Federal Trade Commission (FTC) in April 2021, may not be...
16.04.2018
- US drugmaker Alexion Pharmaceuticals has offered to buy Sweden’s Wilson Therapeutics in a deal worth approximately $855 million. Stockholm-based Wilson develops novel therapies for...
03.07.2015
- Lonza has signed a new long-term product supply agreement with compatriot Alexion Pharmaceuticals. Under the terms of the contract, an expansion of an existing manufacturing...
